Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-07-01 Epub Date: 2024-05-07 DOI:10.1097/MCP.0000000000001079

Ana Collazo-Lorduy, Mariola Blanco, Virginia Calvo, Mariano Provencio

{"title":"Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?","authors":"Ana Collazo-Lorduy, Mariola Blanco, Virginia Calvo, Mariano Provencio","doi":"10.1097/MCP.0000000000001079","DOIUrl":null,"url":null,"abstract":"Purpose of review: Early-stage nonsmall cell lung cancer (NSCLC) accounts for 30% of the total NSCLC, being the stage III a heterogeneous disease that represents a challenge in the management of these patients. Multidisciplinary approach is essential for an adequate treatment strategy, with surgery being the only curative treatment. Neoadjuvant or adjuvant chemotherapy has been the standard of care for a long period, with modest results.Recent findings: Combination of chemotherapy and immunotherapy has revolutionized the neoadjuvant setting of resectable NSCLC, improving pathologic complete responses and survival outcomes in this scenario. Furthermore, perioperative treatment with immunotherapy has also recently shown promising results in several phase III trials.Summary: The landscape of early-stage resectable NSCLC has evolved in recent years, with an improvement in the survival of these patients since the incorporation of immunotherapy in this scenario.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCP.0000000000001079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Early-stage nonsmall cell lung cancer (NSCLC) accounts for 30% of the total NSCLC, being the stage III a heterogeneous disease that represents a challenge in the management of these patients. Multidisciplinary approach is essential for an adequate treatment strategy, with surgery being the only curative treatment. Neoadjuvant or adjuvant chemotherapy has been the standard of care for a long period, with modest results.

Recent findings: Combination of chemotherapy and immunotherapy has revolutionized the neoadjuvant setting of resectable NSCLC, improving pathologic complete responses and survival outcomes in this scenario. Furthermore, perioperative treatment with immunotherapy has also recently shown promising results in several phase III trials.

Summary: The landscape of early-stage resectable NSCLC has evolved in recent years, with an improvement in the survival of these patients since the incorporation of immunotherapy in this scenario.

查看原文本刊更多论文

非小细胞肺癌 III 期的综合治疗：围手术期化疗和免疫疗法该何去何从？

综述的目的：早期非小细胞肺癌（NSCLC）占非小细胞肺癌总数的 30%，III 期是一种异质性疾病，对这些患者的治疗构成了挑战。多学科方法对于制定适当的治疗策略至关重要，而手术是唯一的根治性治疗方法。长期以来，新辅助或辅助化疗一直是标准的治疗方法，但效果一般：化疗与免疫疗法的结合彻底改变了可切除NSCLC的新辅助治疗，改善了病理完全反应和生存率。此外，免疫疗法的围手术期治疗最近也在几项III期试验中显示出了良好的效果。总结：近年来，早期可切除NSCLC的治疗情况发生了变化，自从免疫疗法被纳入这一治疗方案后，这些患者的生存率得到了改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464